Cancer immunotherapy using antibodies that interfere with co-inhibitory molecules such as cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) or programmed cell death protein 1 (PD-1) and its ligand programmed death-ligand 1 (PD-L1) has revolutionized the treatment of various cancer entities. Here, CTLA4 is linked to cancer.